PT2286794T - Uso de lipossomas catiónicos contendo placlitaxel - Google Patents

Uso de lipossomas catiónicos contendo placlitaxel

Info

Publication number
PT2286794T
PT2286794T PT101807501T PT10180750T PT2286794T PT 2286794 T PT2286794 T PT 2286794T PT 101807501 T PT101807501 T PT 101807501T PT 10180750 T PT10180750 T PT 10180750T PT 2286794 T PT2286794 T PT 2286794T
Authority
PT
Portugal
Prior art keywords
paclitaxel
cationic liposomes
liposomes
cationic
Prior art date
Application number
PT101807501T
Other languages
English (en)
Inventor
Teifel Michael
Michaelis Uwe
Sauer Birgitta
Bartelheim Kerstin
Brunner Christoph
Original Assignee
Syncore Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncore Biotechnology Co Ltd filed Critical Syncore Biotechnology Co Ltd
Publication of PT2286794T publication Critical patent/PT2286794T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
PT101807501T 2003-10-15 2004-10-15 Uso de lipossomas catiónicos contendo placlitaxel PT2286794T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023539 2003-10-15
EP04000361 2004-01-09

Publications (1)

Publication Number Publication Date
PT2286794T true PT2286794T (pt) 2016-07-13

Family

ID=34524705

Family Applications (1)

Application Number Title Priority Date Filing Date
PT101807501T PT2286794T (pt) 2003-10-15 2004-10-15 Uso de lipossomas catiónicos contendo placlitaxel

Country Status (11)

Country Link
US (1) US20080063699A1 (pt)
EP (2) EP2286794B8 (pt)
JP (2) JP5645340B2 (pt)
AU (1) AU2004283464B8 (pt)
CA (1) CA2542217C (pt)
DK (1) DK2286794T3 (pt)
ES (1) ES2574231T3 (pt)
HU (1) HUE028648T2 (pt)
PL (1) PL2286794T3 (pt)
PT (1) PT2286794T (pt)
WO (1) WO2005039533A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
PT1853250E (pt) 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9233094B2 (en) 2005-05-04 2016-01-12 Medigene Ag Method of administering a cationic liposomal preparation
WO2007026151A1 (en) * 2005-09-01 2007-03-08 Biolipox Ab Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
KR100658436B1 (ko) * 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
RU2448697C2 (ru) * 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
ATE472998T1 (de) * 2006-05-18 2010-07-15 Medigene Ag Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
MX364637B (es) 2010-03-29 2019-05-03 Abraxis Bioscience Llc Star Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
KR20190130050A (ko) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
EP2598128B1 (en) 2010-07-28 2018-03-28 Life Technologies Corporation Anti- viral azide-containing compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
WO2012075210A2 (en) * 2010-12-01 2012-06-07 Niiki Pharma Inc. Method for treating refractory cancer
DK2714071T3 (da) 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
KR20140129054A (ko) 2012-01-26 2014-11-06 라이프 테크놀로지스 코포레이션 바이러스의 감염성을 증가시키는 방법
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
DE102013009744A1 (de) * 2013-03-26 2014-10-02 Forschungszentrum Jülich GmbH Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA3026452C (en) 2015-06-04 2023-03-21 Crititech, Inc. Nozzle assembly and methods for use
BR112018005200A2 (pt) 2015-09-16 2018-10-09 Dfb Soria Llc liberação de nanopartículas de fármaco e métodos de uso dos mesmos
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
KR102490665B1 (ko) 2016-04-04 2023-01-27 크리티테크, 인크. 고형 종양의 치료 방법
EP3538074B1 (en) * 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
WO2018127082A1 (en) * 2017-01-05 2018-07-12 Syncore Biotechnology Co., Ltd. Treatment of pancreatic cancer
CA3056395C (en) 2017-03-15 2022-06-28 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
ES2980123T3 (es) 2017-06-09 2024-09-30 Crititech Inc Composiciones para uso en el tratamiento de quistes epiteliales mediante inyección intraquística de partículas antineoplásicas
KR20210118468A (ko) 2017-06-14 2021-09-30 크리티테크, 인크. 폐 장애의 치료 방법
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2019178024A1 (en) 2018-03-16 2019-09-19 Dfb Soria, Llc Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes
WO2024160190A1 (zh) * 2023-01-31 2024-08-08 石药集团中奇制药技术（石家庄）有限公司 紫杉醇阳离子脂质体治疗肿瘤的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
DE4430593C2 (de) * 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US7314637B1 (en) * 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
JP4848113B2 (ja) * 1999-09-09 2011-12-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血管新生血管に対するタキサンの陽イオン性リポソーム送達
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
ATE444062T1 (de) * 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
ATE490763T1 (de) * 2002-06-26 2010-12-15 Medigene Ag Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystem

Also Published As

Publication number Publication date
CA2542217C (en) 2018-03-27
EP2286794A1 (en) 2011-02-23
ES2574231T3 (es) 2016-06-16
EP2286794B8 (en) 2016-06-01
AU2004283464B8 (en) 2011-04-14
AU2004283464A1 (en) 2005-05-06
JP2007508353A (ja) 2007-04-05
DK2286794T3 (en) 2016-07-25
EP1673069A1 (en) 2006-06-28
CA2542217A1 (en) 2005-05-06
PL2286794T3 (pl) 2016-10-31
JP2012229255A (ja) 2012-11-22
JP5645340B2 (ja) 2014-12-24
US20080063699A1 (en) 2008-03-13
WO2005039533A1 (en) 2005-05-06
EP2286794B1 (en) 2016-03-30
HUE028648T2 (en) 2016-12-28
EP1673069B1 (en) 2016-10-12
AU2004283464B2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
PL2286794T3 (pl) Zastosowanie kationowych liposomów zawierających paklitaksel
GB0312309D0 (en) Targeted liposome
HK1095082A1 (en) Form of administration secured against misuse
EP1687449A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF KINESIN-LIKE 1
EP1614386A4 (en) ECHOGRAPHIC APPARATUS
ZA200602386B (en) 5-Arylpyrimidines as anticancer agents
EP1665987A4 (en) ULTRASONOGRAPH
EP1446418A4 (en) TARGETING COMPOUNDS OF INTEGRIN
EP1623696A4 (en) COSMETIC PREPARATION ON OIL BASIS
GB0415345D0 (en) Alternating voided areas of anti-pads
GB0305150D0 (en) Use of therapeutic compounds
EP1645265A4 (en) COSMETIC PREPARATION ON OIL BASIS
GB0519079D0 (en) Asthma preperation
IL173851A0 (en) Therapeutic liposomes
IL172407A0 (en) Dna-based aptamers for human cathepsin g
GB0327742D0 (en) Novel uses of known drugs
TWI319322B (en) Frozen-dried preperation containing prostaglandin
HK1087623A1 (en) Combination of antidiabetic drugs
PL377902A1 (pl) Nowe zastosowanie kompleksu fosfor-azot-metal
GB2399559B (en) Construction of container
EP1809245A4 (en) THERAPEUTIC LIPOSOME
AU2003261103A8 (en) Compounds promoting delivery of genes
TW561865U (en) Improvement of curtain
GB0313027D0 (en) Mxximus chest protector
SI2108362T1 (sl) Kationski nosilni sistem, ki vsebuje taksan